CD20xCD3

Glofitamab-gxbm receives FDA approval for relapsing or resistant DLBCL

Glofitamab-gxbm receives FDA approval for relapsing or resistant DLBCL

SG Tylor

Source – Roche Columvi (Glofitamab-gxbm) has been given expedited clearance by the FDA for the treatment of adult patients with ...